Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoCyte Corp OCX

Healthcare Biotechnology
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict... see more

Recent & Breaking News (NDAQ:OCX)

Oncocyte to Hold KOL Webinar Showcasing New Data and Real World Usage of DetermaRx(TM)

GlobeNewswire July 23, 2020

Oncocyte to Report Second Quarter 2020 Financial Results on Wednesday, July 29

GlobeNewswire July 20, 2020

Oncocyte Announces Final Local Coverage Determination from Noridian Healthcare Solutions for DetermaRx(TM), Securing National Medicare Payment for the Test Starting August 2020

GlobeNewswire July 20, 2020

Oncocyte Announces Distribution Agreement with ProGenetics Ltd, Expanding Commercial Availability of DetermaRx(TM) to Israel

GlobeNewswire July 16, 2020

Oncocyte Provides an Update on the Rapid Growth of DetermaRx(TM) Physician Adoption and Testing Volume

GlobeNewswire July 14, 2020

Oncocyte Announces Completion of DetermaDx(TM) Clinical Validation Study

GlobeNewswire June 29, 2020

Oncocyte Transitions to Revenue Generation as Multiple Payers Begin DetermaRx(TM) Reimbursements

GlobeNewswire June 15, 2020

Oncocyte Announces New Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrating That the DetermaIO(TM) Gene Expression Test May Predict Response to Immunotherapy in Triple Negative Breast Cancer

GlobeNewswire May 13, 2020

Oncocyte Provides Corporate Update And Reports First Quarter 2020 Financial Results

GlobeNewswire May 12, 2020

Oncocyte Announces Peer-Reviewed Publication of Data Demonstrating the Potential of its TNBCType Assay to Inform Triple Negative Breast Cancer Drug Development

GlobeNewswire May 5, 2020

Oncocyte to Report First Quarter 2020 Financial Results on Tuesday, May 12

GlobeNewswire May 5, 2020

Oncocyte Announces the Publication of New Long-Term Patient Follow Up Data for DetermaRx(TM) and Research Describing the IRENE Cohort Being Used in the Development of DetermaDx(TM)

GlobeNewswire May 1, 2020

Oncocyte Announces Final Medicare LCD from Palmetto for DetermaRx(TM)

GlobeNewswire April 30, 2020

Oncocyte Announces $10.7 Million Registered Offering

GlobeNewswire April 24, 2020

Oncocyte Announces Distribution Agreement with CORE Diagnostics, Expanding Commercial Availability of DetermaRx(TM) to India, the Middle East and Africa

GlobeNewswire April 23, 2020

Oncocyte to Participate at 19th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 7, 2020

ONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

GlobeNewswire March 25, 2020

Oncocyte Announces the Launch of CLIA-validated DetermaIO(TM), a Novel Gene Expression-Based Immune Therapy Response Predictor, for Research Use by Biopharmaceutical Companies and Researchers

GlobeNewswire March 19, 2020

ONCOCYTE TO REPORT FOURTH QUARTER AND FISCAL 2019 FINANCIAL RESULTS ON WEDNESDAY, MARCH 25

GlobeNewswire March 18, 2020

Oncocyte Closes Merger Agreement to Acquire Insight Genetics

GlobeNewswire February 5, 2020